Investors
We use materials science to make consumer products that are more satisfying and design medicines that give patients better control over their treatments.
Our broad project portfolio is backed by solid IP in key pharmaceutical and consumer markets. We are well positioned for licensing deals in major markets.
Stora Aktiedagen Stockholm November 30, 2022
CEO Håkan Engqvist meets investors and media
CEO Håkan Engqvist presents Emplicure to investors and media and fields questions on a number of topics, including the marketing strategy for the company’s innovative nicotine pouches in the Nordics as well as in global markets.
“We firmly believe that if we come to market with a very small pouch and deliver in the same way that a large pouch delivers, that we will be able to take market share in the Nordics too.”
Amplicon
Our bioceramic platform makes our tiny, flavor-packed and long-lasting nicotine pouches more satisfying, letting consumers feel more liberated. Together with partners, we intend to help millions of smokers switch to oral nicotine punches.
Emplipharm
We are developing an oral, buccal tablet that delivers buprenorphine with properties that counteract abuse. We are advancing formulation development to increase the initial release profile of buprenorphine after the exploratory pharmacokinetic study of Empli03 showed a steady extended release.
800+
Investors
7
Patent families
53
Patents
2014
Founded
Technology for improved experiences
Our products target large and growing markets or significant unmet medical needs.
Our two business areas advance innovative products based on our patented bioceramic platforms and existing and approved molecules and pharmaceutical ingredients.